Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AFM28
- Development stage
- Preclinical
- Lead developer
- Affimed
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AFM28 is a high-affinity bispecific, tetravalent antibody-based construct designed to engage natural killer (NK) cells for the treatment of CD123-expressing hematological malignancies, primarily acute myeloid leukemia (AML). It works by binding to CD16A on NK cells and CD123 on leukemic cells, redirecting NK cell cytotoxicity toward malignant blasts and leukemic stem/progenitor cells. This mechanism enables targeted elimination of AML cells while sparing healthy tissue. Developed by Affimed, AFM28 has demonstrated preliminary clinical efficacy and a manageable safety profile in phase 1 studies involving relapsed/refractory AML patients. The drug is also being explored for potential use in combination with allogeneic NK cell therapy and may have future applications in other CD123-positive malignancies[1][2][3][4][5].
- Other names
- AFM28AFM-28AFM 28
02
Targets
IL3RA (Interleukin 3 Receptor)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on AFM28.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AFM28.